Clinical Trial

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The goal of this study is to evaluate, over a 12-week induction period, the safety and efficacy of mirikizumab in patients with moderately to severely active UC who have an inadequate response to, loss of response to, or are intolerant to corticosteroid or immunomodulator therapy for UC (termed “conventionalfailed”), and those who have an inadequate response to, loss of response to, or are intolerant to biologic therapy for UC (termed “biologic-failed”).

Information

Principal Investigator Sriramachandra Badiga, MD
Co-PI
Sponsor
Type of Trial Prospective/Interventional